Chronic Kidney Disease Market: 10-Year Growth Projections and Regional Insights
25 nov. 2024 07h13 HE
|
Research and Markets
Dublin, Nov. 25, 2024 (GLOBE NEWSWIRE) -- The "Chronic Kidney Disease: 68-Market Analysis and Sales Forecast" report has been added to ResearchAndMarkets.com's offering.This report covers the 68...
American Kidney Fund’s Second Patient Access Initiative Summit Will Highlight Health Care Challenges Faced by Kidney Community, Outline Public Policy Solutions
19 nov. 2024 09h18 HE
|
American Kidney Fund
ROCKVILLE, Md., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Today, the American Kidney Fund (AKF) will host its second Patient Access Initiative (PAI) Summit—part of AKF’s ongoing work to address health care...
Hope on the Horizon: Nephrologists Emphasize Need for Innovative C3G Treatments as Novartis and Apellis Prepare Therapies for FDA Submission
15 nov. 2024 13h15 HE
|
Spherix Global Insights
EXTON, PA, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Complement 3 glomerulopathy (C3G) is a rare, progressive kidney disease characterized by inflammation and kidney damage. Patients with C3G often...
ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update
14 nov. 2024 08h10 HE
|
ZyVersa Therapeutics
ZyVersa announces progress toward achieving key near-term development milestones and Q3-2024 financials.
Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024
28 oct. 2024 07h03 HE
|
Unicycive Therapeutics, Inc.
– Late-Breaker Poster Presentation Highlights Favorable Safety & Tolerability of OLC – – Two Publications Recently Issued Featuring OLC and UNI-494 – LOS ALTOS, Calif., Oct....
The American Kidney Fund Launches ‘Answers Unlocked’ Educational Campaign to Help Kidney Patients Learn About the Benefits of Genetic Testing
22 oct. 2024 12h17 HE
|
American Kidney Fund
ROCKVILLE, Md., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Today, the American Kidney Fund (AKF) launched its newest educational campaign, “Answers Unlocked,” to spread awareness of the need and benefits of...
Unicycive Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024
16 oct. 2024 16h35 HE
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
On the Heels of Historic Hurricane Helene, American Kidney Fund Activates Disaster Relief Program to Support Dialysis and Post-Transplant Patients Affected by Hurricane Milton
10 oct. 2024 13h07 HE
|
American Kidney Fund
ROCKVILLE, Md., Oct. 10, 2024 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) has turned on its Disaster Relief Program to aid dialysis and post-transplant patients living in areas impacted by...
Unicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy Volunteers
09 oct. 2024 07h03 HE
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases
09 oct. 2024 07h00 HE
|
Purespring Therapeutics
Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases Oversubscribed financing led by Sofinnova Partners in collaboration with Gilde...